Valeant Earnings: A 12-Month Journey to Nowhere?

What goes down must go up, but it doesn’t have to stay there. Just ask Valeant Pharmaceuticals International (VRX). Heading into this morning’s fourth-quarter earnings release, the beaten-down specialty pharmaceutical company had seen its market value triple since bottoming in April 2016. And then its earnings were released. It wasn’t that the numbers were terrible. […]
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>